{"filings":[{"id":90637,"accession_number":"0001193125-26-197129","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q1 revenue up 23% to $59.9M, raises FY product revenue guidance","event_type":"earnings","confidence":"high","bullets":["Product revenue $53.7M (+24% YoY); total revenue $59.9M (+23% YoY).","Net loss improved to $1.6M ($0.01/sh) from $7.7M ($0.04/sh) a year ago; Non-GAAP adjusted EBITDA $4.0M vs $0.2M.","Raises full-year 2026 product revenue guidance to $227M-$231M (was $224M-$228M); IFC revenue guided $22M-$24M.","Signed 4-year supply agreement with Établissement Français du Sang (EFS) for INTERCEPT Blood System and INT200.","CEO transition: COO Vivek Jayaraman to become CEO effective July 1, 2026; current CEO William Greenman to become executive chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":53661000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90636,"accession_number":"0001020214-26-000007","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cerus adopts severance plan for top officers; CFO, COO, CMO, CLO covered","event_type":"other_material","confidence":"high","bullets":["Severance plan provides 1.5x-2x salary and bonus multiples, COBRA coverage, and full equity acceleration on change-in-control termination.","Participants: CFO Kevin Green, COO Vivek Jayaraman, CMO Richard Benjamin, CLO Chrystal Jensen.","Non-change-in-control severance for Green, Jensen, and Jayaraman (as COO) includes 12 months base salary and COBRA; Jayaraman as CEO gets enhanced benefits.","Plan supersedes all prior severance arrangements for these officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100324,"accession_number":"0001193125-26-108629","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cerus names Vivek Jayaraman as President and CEO, effective July 1, 2026","event_type":"leadership","confidence":"high","bullets":["Vivek Jayaraman, current COO, will become President and CEO effective July 1, 2026; current CEO Obi Greenman becomes Executive Chairman.","Jayaraman's base salary $740,000; target bonus up to 80% of base salary.","Promotion equity award of $2M (75% time-based RSUs, 25% performance-based RSUs); additional $1M achievement award (performance-based RSUs).","Severance: 12 months base salary plus COBRA continuation and full acceleration of unvested equity upon qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100323,"accession_number":"0001193125-26-085350","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports FY2025 revenue $233.8M (+16%); net loss narrows to $15.6M","event_type":"earnings","confidence":"high","bullets":["FY2025 product revenue $206.1M (+14%); total revenue $233.8M (+16%).","Net loss attributable to Cerus $15.6M ($0.08/share) vs $20.9M ($0.11) in 2024.","Non-GAAP adjusted EBITDA $9.5M, up from $5.7M; second consecutive positive year.","IFC demand more than doubled; revenue ~$16.7M (+80%); Q4 U.S. IFC sales $4.2M.","FY2026 product revenue guidance $224M-$228M, representing 9-11% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100322,"accession_number":"0001193125-26-021085","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Timothy L. Moore not seeking re-election at Cerus 2026 annual meeting","event_type":"leadership","confidence":"high","bullets":["Moore informed Cerus on Jan 19, 2026 he will not stand for re-election at the 2026 annual meeting.","Decision not due to any disagreement with company operations, policies, or practices.","His term expires at the 2026 annual meeting; no replacement named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100321,"accession_number":"0001193125-26-009824","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports preliminary FY 2025 product revenue of $206.1M (+14% YoY); guides FY 2026 to $224-228M","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary product revenue $57.8M, up 14% YoY; IFC revenue $4.2M (+40% YoY).","FY 2025 product revenue $206.1M (+14% YoY); IFC contributed $16.7M (+82% YoY).","FY 2026 product revenue guidance $224-228M (9-11% growth); IFC expected $20-22M.","PMA submission for INT200 LED illumination device expected mid-2026; Phase 3 RBC study results H2 2026.","Complete FY 2025 financial results and business update call planned for early March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":233798000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116657,"accession_number":"0001193125-25-269451","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q3 revenue up 19% to $60.2M, raises FY2025 product revenue guidance","event_type":"earnings","confidence":"high","bullets":["Product revenue $52.7M (+15% YoY); total revenue $60.2M (+19% YoY).","GAAP net loss narrowed to $0.02M (near breakeven); non-GAAP adjusted EBITDA $5.0M.","U.S. IFC sales $3.9M, volumes up ~110% YoY; hospital demand increasing.","Full-year 2025 product revenue guidance raised to $202-204M (prev. $200-203M).","Cash and investments $78.5M; generated $1.9M operating cash flow in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133099,"accession_number":"0000950170-25-102976","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q2 product revenue $52.4M (+16% YoY); raises FY2025 guidance to $200-203M","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue record $52.4M, up 16% YoY; total revenue $60.1M, up 19% YoY.","Net loss $5.7M ($0.03/sh), narrowing from $5.8M; positive non-GAAP adjusted EBITDA of $0.9M.","IFC revenue $5.6M vs $2.0M prior year; full-year IFC guidance raised to $16-18M (from $12-15M).","Full-year product revenue guidance raised to $200-203M (prior $194-200M) on strong H1 performance.","Cash $78M; DoD awarded $7.2M for lyophilized IFC development; RBC CE Mark under EU review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149698,"accession_number":"0000950170-25-089029","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cerus board chair Swisher retires; CEO Greenman named chair, Witney lead independent director","event_type":"leadership","confidence":"high","bullets":["Daniel N. Swisher, Jr., chair of the board, retired effective June 16, 2025; no disagreement with the company.","William M. Greenman, President and CEO, appointed chair of the board effective June 20, 2025.","Frank Witney, Ph.D., appointed lead independent director, effective June 20, 2025.","Swisher also left all board committees upon retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149697,"accession_number":"0000950170-25-083561","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cerus shareholders elect two directors, approve equity plan amendment at 2025 annual meeting","event_type":"other_material","confidence":"high","bullets":["Jami Dover Nachtsheim and Hua Shan elected to board with 107.0M and 111.4M votes for, respectively.","Amendment and restatement of 2024 Equity Incentive Plan approved: 74.3M for, 39.5M against.","Advisory say-on-pay vote passed: 104.5M for, 9.3M against, 206K abstentions.","Ernst & Young ratified as independent auditor for FY2025: 153.2M for, 4.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}